Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Neurocrit Care ; 33(3): 725-731, 2020 12.
Article in English | MEDLINE | ID: mdl-32212038

ABSTRACT

BACKGROUND: Intracranial hemorrhage (ICH) may occur in patients admitted to the hospital for unrelated medical conditions, resulting in prolonged hospitalization and worse prognosis. We aim to assess the clinical presentation and outcomes of in-hospital ICH compared to patients with ICH presenting from the community. METHODS: We conducted a retrospective analysis of all acute stroke alerts diagnosed with ICH in an urban academic hospital over a 4-year period. Demographics, clinical presentation, use of antithrombotic therapy, and presence of coagulopathy were recorded. ICH score and a sequential organ failure assessment score were calculated during the initial assessment. Initial head computed tomography was reviewed to determine ICH subtype, location, and volume of the hematoma. In-hospital mortality and discharge disposition were used as surrogate of clinical outcome. RESULTS: From the 1965 stroke alert cases analyzed over the studied years, 145 (7.4%) were diagnosed with ICH. Overall, the mean age was 62.9 ± 13.9 and 53.7% were women. Thirty-two patients (22%) developed ICH in the inpatient setting and 113 (78%) presented from the community. Systolic blood pressure at presentation was lower in the in-hospital group (p < 0.01). Inpatients who developed ICH were more likely than community ICH patients to be on combination of antiplatelet agents (21.9% vs. 5.3%, p < 0.05) or therapeutic heparinoids (21.9% vs. 0.9%, p < 0.01). Also, In-hospital ICH patients had a higher rate of spontaneous or iatrogenic coagulopathy (65.6% vs. 10.6%, p < 0.01) and thrombocytopenia (31.3% vs. 1.8%, p < 0.01). Lobar hemorrhages were more prevalent in the in-hospital group (82.6% vs. 39.1%, p < 0.01) and the mean hematoma volume was higher (40.9 ± 43.1 mL vs. 24.1 ± 30.4 mL; p < 0.02). Median ICH score in the in-hospital group was not statistically different from the emergency department group: 2 (IQR: 0-3) versus 1 (IQR: 0-3). When comparing patients with in-hospital ICH and those from the community, the short-term mortality was higher in the former group (81% vs. 31%, p < 0.01). The incidence of withdrawal of life-sustaining therapies as a proximate mechanism of death was higher, but not statistically significant, in the in-hospital group (86% vs. 61%). CONCLUSION: ICH is a critical complication in the inpatient setting, predominantly occurring in already ill patients with underlying spontaneous or iatrogenic coagulopathy. Large volume lobar intraparenchymal hemorrhage is a common radiographic finding. ICH is frequently a catastrophic event and powerfully weighs in with end-of-life discussion, resulting in high short-term mortality rate.


Subject(s)
Cerebral Hemorrhage , Stroke , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/mortality , Female , Hematoma , Humans , Intracranial Hemorrhages/diagnostic imaging , Intracranial Hemorrhages/mortality , Middle Aged , Retrospective Studies
2.
J Stroke Cerebrovasc Dis ; 29(5): 104692, 2020 May.
Article in English | MEDLINE | ID: mdl-32085938

ABSTRACT

BACKGROUND AND AIM: Patients with in-hospital acute ischemic stroke (AIS) have, in general, worse outcomes compared to those presenting from the community, partly attributed to the numerous contraindications to intravenous thrombolysis. We aimed to identify and analyze a group of patients with in-hospital AIS who remain suitable candidates for acute endovascular therapies. METHODS: A retrospective 6-year data analysis was conducted in patients evaluated through the in-hospital stroke alert protocol in a single tertiary care university hospital to identify those with in-hospital AIS due to acute intracranial large vessel occlusion (ILVO). Feasibility and safety of mechanical thrombectomy for in-hospital AIS was assessed in a case-control study comparing inpatients to those presenting from the community. RESULTS: From 1460 in-hospital stroke alert activations, 11% had a final diagnosis of AIS (n = 167). One hundred and two patients with in-hospital AIS had emergent intracranial vessel imaging and were included in our cohort. Acute ILVO was identified in 27 patients within this cohort. Patients were younger in the ILVO group and had more severe neurologic deficit on presentation. Compared to a matched (1:2) control group of patients presenting from the community, inpatients who underwent mechanical thrombectomy achieved equivalent technical success, safety, and clinical outcomes. CONCLUSIONS: The incidence of acute ILVO in patients with in-hospital AIS who underwent emergent vessel imaging is similar to the reported incidence of ILVO in patients presenting with community-onset AIS. Among patients with in-hospital AIS secondary to ILVO, mechanical thrombectomy is a feasible and safe therapy associated with favorable outcomes.


Subject(s)
Brain Ischemia/therapy , Inpatients , Intracranial Thrombosis/therapy , Stroke/therapy , Thrombectomy , Aged , Brain Ischemia/diagnostic imaging , Brain Ischemia/epidemiology , Brain Ischemia/physiopathology , Feasibility Studies , Female , Humans , Incidence , Intracranial Thrombosis/diagnostic imaging , Intracranial Thrombosis/epidemiology , Intracranial Thrombosis/physiopathology , Male , Middle Aged , Retrospective Studies , Stroke/diagnostic imaging , Stroke/epidemiology , Stroke/physiopathology , Thrombectomy/adverse effects , Time Factors , Treatment Outcome
3.
Neurosci Lett ; 661: 126-131, 2017 Nov 20.
Article in English | MEDLINE | ID: mdl-28982595

ABSTRACT

BACKGROUND AND PURPOSE: Ischemic stroke produces significant morbidity and mortality, and acute interventions are limited by short therapeutic windows. Novel approaches to neuroprotection and neurorepair are necessary. HuR is an RNA-binding protein (RBP) which modulates RNA stability and translational efficiency of genes linked to ischemic stroke injury. METHODS: Using a transgenic (Tg) mouse model, we examined the impact of ectopic HuR expression in astrocytes on acute injury evolution after transient middle cerebral artery occlusion (tMCAO). RESULTS: HuR transgene expression was detected in astrocytes in perilesional regions and contralaterally. HuR Tg mice did not improve neurologically 72h after injury, whereas littermate controls did. In Tg mice, increased cerebral vascular permeability and edema were observed. Infarct volume was not affected by the presence of the transgene. CONCLUSIONS: Ectopic expression of HuR in astrocytes worsens outcome after transient ischemic stroke in mice in part by increasing vasogenic cerebral edema. These findings suggest that HuR could be a therapeutic target in cerebral ischemia/reperfusion.


Subject(s)
Brain Edema/metabolism , Brain Ischemia/metabolism , ELAV-Like Protein 1/metabolism , Infarction, Middle Cerebral Artery/metabolism , Recovery of Function/physiology , Animals , Brain/metabolism , Brain/physiopathology , Brain Edema/genetics , Brain Ischemia/genetics , Disease Models, Animal , ELAV-Like Protein 1/genetics , Infarction, Middle Cerebral Artery/genetics , Mice, Transgenic , Recovery of Function/genetics , Reperfusion Injury/metabolism , Stroke/physiopathology
4.
Neurohospitalist ; 7(4): 179-187, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28974996

ABSTRACT

BACKGROUND: Continuous electroencephalography (CEEG) is a sensitive, noninvasive surrogate monitor of cerebral blood flow (CBF). Changes in CBF can be seen as changes in the frequencies on the CEEG. This case series suggests that increase in CEEG frequencies may be used to detect improved CBF following pressure augmentation such as with treatment of vasospasm from subarachnoid hemorrhage (SAH) or acute thrombosis from ischemic stroke. The application of this observation to clinical decision-making has not been clearly defined and requires further study. METHODS: Case series and imaging. RESULTS: We present 3 patients with ischemic penumbras either from vasospasm from SAH or thrombosis from acute ischemic stroke. All patients were monitored on CEEG and found to have lateralized slowing. During pressure augmentation, the lateralized slowing improved in frequency, which corresponded with improvement in the patients' neurological examinations. CONCLUSION: Continuous electroencephalography may be used as a noninvasive monitor to allow for individualization of pressure augmentation in cases of vasospasm from SAH or in cases of acute ischemic strokes. This customized approach may allow for less morbidity associated with pressure augmentation in patients who otherwise may have dysfunction of their intracerebral autoregulation.

5.
Brain Res ; 1639: 200-13, 2016 05 15.
Article in English | MEDLINE | ID: mdl-26995494

ABSTRACT

Estrogens have previously been shown to protect the brain against acute ischemic insults, by potentially augmenting cerebrovascular function after ischemic stroke. The current study hypothesized that treatment with sustained release of high-dose 17ß-estradiol (E2) at the time of reperfusion from middle cerebral artery occlusion (MCAO) in rats would attenuate reperfusion injury, augment post-stroke angiogenesis and cerebral blood flow, and attenuate lesion volume. Female Wistar rats underwent ovariectomy, followed two weeks later by transient, two-hour right MCAO (tMCAO) and treatment with E2 (n=13) or placebo (P; n=12) pellets starting at reperfusion. E2 treatment resulted in significantly smaller total lesion volume, smaller lesions within striatal and cortical brain regions, and less atrophy of the ipsilateral hemisphere after six weeks of recovery. E2-treated animals exhibited accelerated recovery of contralateral forelimb sensorimotor function in the cylinder test. Magnetic resonance imaging (MRI) showed that E2 treatment reduced the formation of lesion cysts, decreased lesion volume, and increased lesional cerebral blood flow (CBF). K(trans), a measure of vascular permeability, was increased in the lesions. This finding, which represents lesion neovascularization, was not altered by E2 treatment. Ischemic stroke-related angiogenesis and vessel formation was confirmed with immunolabeling of brain tissue and was not altered with E2 treatment. In summary, E2 treatment administered immediately following reperfusion significantly reduced lesion size, cyst formation, and brain atrophy while improving lesional CBF and accelerating recovery of functional deficits in a rat model of ischemic stroke.


Subject(s)
Brain Ischemia/drug therapy , Estradiol/administration & dosage , Neuroprotective Agents/administration & dosage , Reperfusion Injury/drug therapy , Stroke/drug therapy , Animals , Brain/diagnostic imaging , Brain/drug effects , Brain/pathology , Brain/physiopathology , Brain Ischemia/diagnostic imaging , Brain Ischemia/pathology , Brain Ischemia/physiopathology , Cerebrovascular Circulation/drug effects , Cerebrovascular Circulation/physiology , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Implants , Estradiol/blood , Female , Forelimb/physiopathology , Motor Activity/drug effects , Motor Activity/physiology , Neuroprotective Agents/blood , Ovariectomy , Random Allocation , Rats, Wistar , Recovery of Function/drug effects , Recovery of Function/physiology , Reperfusion Injury/diagnostic imaging , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Stroke/diagnostic imaging , Stroke/pathology , Stroke/physiopathology
6.
Exp Neurol ; 248: 246-53, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23811016

ABSTRACT

In response to ischemic injury, the brain mounts a repair process involving the development of new neurons, oligodendrocytes, and astrocytes. However, the manner in which new neurons integrate into existing brain circuitry is not well understood. Here we observed that during the four weeks after transient middle cerebral artery occlusion (MCAO), doublecortin (DCX)-expressing neural progenitors originating in the subventricular zone (SVZ) were present in the ischemic lesion borderzone, where they received γ-aminobutyric acid (GABA) inputs, a feature that is common to newly developing neurons. The chemokine stromal derived factor-1 (SDF-1 or CXCL12) was enriched in lesional endothelial and microglial cells for up to four weeks after transient MCAO, and application of SDF-1 to acute brain slices enhanced GABAergic inputs to the new neurons. These observations suggest that SDF-1 is in a position to coordinate neovascularization and neurogenesis during the repair process after cerebral ischemia-reperfusion.


Subject(s)
Brain Ischemia/metabolism , Cerebral Cortex/metabolism , Chemokine CXCL12/metabolism , Neurons/metabolism , Synaptic Transmission/physiology , Animals , Brain Ischemia/physiopathology , Cell Proliferation , Cerebral Cortex/physiopathology , Chemokine CXCL12/genetics , Doublecortin Domain Proteins , Doublecortin Protein , Endothelial Cells/metabolism , Mice , Mice, Transgenic , Microglia/metabolism , Microtubule-Associated Proteins/metabolism , Neovascularization, Physiologic/physiology , Neural Stem Cells/metabolism , Neurogenesis/physiology , Neuropeptides/metabolism
8.
Brain Res ; 1461: 76-86, 2012 Jun 21.
Article in English | MEDLINE | ID: mdl-22572084

ABSTRACT

We previously observed that 17ß-estradiol (E2) augments ischemic borderzone vascular density 10 days after focal cerebral ischemia-reperfusion in rats. We now evaluated the effect of E2 on vascular remodeling, lesional characteristics, and motor recovery up to 30 days after injury. Peri-lesional vascular density in tissue sections from rats treated with 0.72 mg E2 pellets was higher compared to 0.18 mg E2 pellets or placebo (P) pellets: vascular density index, 1.9 ± 0.2 (0.72 mg E2) vs. 1.4 ± 0.2 (0.18 mg E2) vs. 1.5 ± 0.4 (P), p=0.01. This was consistent with perfusion magnetic resonance imaging (MRI) measurements of lesional relative cerebral blood flow (rCBF): 1.89 ± 0.32 (0.72 mg E2) vs. 1.32 ± 0.19 (P), p=0.04. Post-ischemic angiogenesis occurred in P-treated as well as E2-treated rats. There was no treatment-related effect on lesional size, but lesional tissue was better preserved in E2-treated rats: cystic component as a % of total lesion, 30 ± 12 (0.72 mg E2) vs. 29 ± 17 (0.18 mg E2) vs. 61 ± 29 (P), p=0.008. Three weeks after right middle cerebral artery territory injury, rats treated with 0.72 mg E2 pellets used the left forelimb more than P-treated or 0.18 mg E2-treated rats: limb use asymmetry score, 0.09 ± 0.43 (0.72 mg E2) vs. 0.54 ± 0.12 (0.18 mg E2) vs. 0.54 ± 0.40 (P), p=0.05. We conclude that treatment with 0.72 mg E2 pellets beginning one week prior to ischemia/reperfusion and continuing through the one-month recovery period results in augmentation of lesional vascularity and perfusion, as well as improved motor recovery.


Subject(s)
Brain Ischemia/drug therapy , Cerebrovascular Circulation/drug effects , Disease Models, Animal , Estradiol/therapeutic use , Recovery of Function/drug effects , Stroke/drug therapy , Animals , Brain Ischemia/physiopathology , Cerebrovascular Circulation/physiology , Estradiol/pharmacology , Female , Rats , Rats, Wistar , Recovery of Function/physiology , Stroke/physiopathology , Time Factors , Treatment Outcome
9.
J Neuroimmunol ; 246(1-2): 34-7, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22445740

ABSTRACT

In experimental autoimmune encephalomyelitis (EAE) and other neurodegenerative diseases, astrocytes play an important role in promoting or attenuating the inflammatory response through induction of different cytokines and growth factors. HuR plays a major role in regulating many of these factors by modulating RNA stability and translational efficiency. Here, we engineered transgenic mice to express HuR in astrocytes using the human glial fibrillary acidic protein promoter and found that female transgenic mice had significantly less clinical disability and histopathological changes in the spinal cord. Ovariectomy prior to EAE induction abrogated the protective effect. Our findings support a role for the astrocyte and posttranscriptional regulation in hormonally-mediated attenuation of EAE.


Subject(s)
Astrocytes/metabolism , ELAV Proteins/biosynthesis , ELAV Proteins/genetics , Encephalomyelitis, Autoimmune, Experimental/genetics , Encephalomyelitis, Autoimmune, Experimental/pathology , Estradiol Congeners/physiology , Gene Expression Regulation/immunology , Animals , Astrocytes/immunology , Astrocytes/pathology , ELAV Proteins/physiology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Female , Humans , Mice , Mice, Transgenic , Spinal Cord/immunology , Spinal Cord/metabolism , Spinal Cord/pathology
10.
Surg Neurol Int ; 2: 117, 2011.
Article in English | MEDLINE | ID: mdl-21918732

ABSTRACT

BACKGROUND: Acute hydrocephalus (HCP) after aneurysmal subarachnoid hemorrhage (SAH) often persists. Our previous study described factors that singly and combined in a formula correlate with permanent CSF diversion. We now aimed to determine whether the same parameters are applicable at an institution with different HCP management practice. METHODS: We reviewed records of 181 consecutive patients who presented with SAH and received an external ventricular drain (EVD) for acute HCP. After exclusion and inclusion criteria were met, 71 patients were analyzed. Data included admission Fisher and Hunt and Hess grades, aneurysm location, treatment modality, ventricle size, CSF cell counts and protein levels, length of stay (LOS) in the hospital, and the presence of craniectomy. Outcome measures were: (1) initial EVD challenge outcome; (2) shunting within 3 months; and (3) LOS. RESULTS: Shunting correlated with Hunt and Hess grade, CSF protein, and the presence of craniectomy. The formula derived in our previous study demonstrated a weaker correlation with initial EVD challenge failure. Several parameters that correlated with shunting in the previous study were instead associated with LOS in this study. CONCLUSIONS: The decision to shunt depends on management choices in the context of a disease process that may improve over time. Based on the treatment strategy, the shunting rate may be lowered but LOS increased. Markers of disease severity in patients with HCP after SAH correlate with both shunt placement and LOS. This is the first study to directly evaluate the effect of different practice styles on the shunting rate. Differences in HCP management practices should inform the design of prospective studies.

11.
Neurosurgery ; 67(4): 935-9; discussion 939-40, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20881558

ABSTRACT

BACKGROUND: Long-term administration of the antifibrinolytic agent epsilon aminocaproic acid (EACA) reduces the rate of rehemorrhage in patients with aneurysmal subarachnoid hemorrhage (SAH), but is associated with cerebral ischemia. OBJECTIVE: To evaluate short-term administration of EACA before early surgery in patients with SAH. METHODS: Retrospective review of 356 patients admitted between June 2002 and December 2007 with a diagnosis of aneurysmal SAH. Medical records were reviewed to determine SAH risk factors, clinical grade at the time of admission, and incidence of rehemorrhage, permanent new-onset focal neurological deficits, computed tomography evidence of cerebral infarction, symptomatic vasospasm, and hydrocephalus. RESULTS: Patients underwent treatment of the ruptured aneurysm an average of 47.4 hours after admission and received an average total dose of 40.6 g of EACA. The mean length of time of administration of EACA was 35.6 hours. There was a total of 5 rehemorrhages, for an overall rebleeding rate of 1.4% and a rate of rehemorrhage per 24-hour period of 0.71%. Overall, the rates of symptomatic vasospasm and permanent neurological deficits attributable to ischemic stroke were 11.5% and 7.2%, respectively, and the incidence of shunt-dependent hydrocephalus was 42.3%. Patients who were treated with coiling had higher rates of symptomatic vasospasm and ischemic complications than patients who had surgery. CONCLUSION: Short-term administration of EACA is associated with rates of rehemorrhage, ischemic stroke, and symptomatic vasospasm that compare favorably with historical controls. The rate of hydrocephalus is relatively high and may be attributable to EACA treatment.


Subject(s)
Aminocaproic Acid/adverse effects , Antifibrinolytic Agents/adverse effects , Brain Ischemia/chemically induced , Hydrocephalus/chemically induced , Subarachnoid Hemorrhage/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Vasospasm, Intracranial/chemically induced , Young Adult
12.
J Histochem Cytochem ; 58(1): 53-60, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19786610

ABSTRACT

Angiopoietin-1 (Angpt1; previously Ang-1) participates in vascular maintenance and remodeling. In the current study, we investigated the distribution of Angpt1 protein in rat brain. We detected Angpt1 immunoreactivity (IR) in cerebral blood vessels, cuboidal ependyma, and tanycytes, which are specialized hypothalamic bipolar ependymal cells. We also evaluated patterns of IR of endothelium-specific receptor tyrosine kinase 2 (Tie2, the receptor for Angpt1). Tie2 IR was present in Angpt1-immunoreactive cuboidal ependyma in a membranous pattern, suggesting an autocrine or paracrine role for Angpt1-Tie2. Tie2 IR was also associated with peri-ependymal blood vessels, some of which were contacted by tips of Angpt1-immunoreactive tanycyte processes, implying a potential functional ligand-receptor interaction mediating communication between the cerebrospinal fluid and vascular compartments. Because we previously found that cerebral Angpt1 expression was modulated by 17beta-estradiol (E2), and because some tanycyte functions are modulated by E2, we tested the hypothesis that E2 affects ependymal and tanycyte Angpt1 expression in vivo. No gross E2 effect on the ependymal pattern of Angpt1 IR or cerebral Angpt1 protein content was observed.


Subject(s)
Angiopoietin-1/analogs & derivatives , Blood Vessels/metabolism , Ependyma/metabolism , Hypothalamus/metabolism , Receptor, TIE-2/metabolism , Angiopoietin-1/immunology , Angiopoietin-1/metabolism , Animals , Antibodies , Astrocytes/metabolism , Blotting, Western , Estradiol/blood , Female , Lectins , Male , Pericytes/metabolism , Rats , Rats, Wistar
13.
Stroke ; 39(4): 1197-204, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18323502

ABSTRACT

BACKGROUND AND PURPOSE: Evaluation of posterior circulation with single-gate transcranial Doppler (TCD) is technically challenging and yields lower accuracy parameters in comparison to anterior circulation vessels. Transcranial power motion-mode Doppler (PMD-TCD), in addition to spectral information, simultaneously displays in real-time flow signal intensity and direction over 6 cm of intracranial space. We aimed to evaluate the diagnostic accuracy of PMD-TCD against angiography in detection of acute posterior circulation stenoocclusive disease. METHODS: Consecutive patients presenting to the emergency room with symptoms of acute (<24 hours) cerebral ischemia underwent emergent neurovascular evaluation with PMD-TCD and angiography (computed tomographic angiography, magnetic resonance angiography, or digital subtraction angiography). Previously published diagnostic criteria were prospectively applied for PMD-TCD interpretation independent of angiographic findings. RESULTS: A total of 213 patients (119 men; mean age 65+/-16 years; ischemic stroke 71%, transient ischemic attack 29%) underwent emergent neurovascular assessment. Compared with angiography, PMD-TCD showed 17 true-positive, 8 false-negative, 6 false-positive, and 182 true-negative studies in posterior circulation vessels (sensitivity 73% [55% to 91%], specificity 96% [93% to 99%], positive predictive value 68% [50% to 86%], negative predictive value 95% [92% to 98%], accuracy 93% [90% to 96%]). In 14 patients (82% of true-positive cases), PMD display showed diagnostic flow signatures complementary to the information provided by the spectral display: reverberating or alternating flow, distal basilar artery flow reversal, high-resistance flow, emboli tracks and, bruit flow signatures. CONCLUSIONS: PMD-TCD yields a satisfactory agreement with urgent brain angiography in the evaluation of patients with acute posterior circulation cerebral ischemia. PMD display can depict flow signatures that are complimentary to and can increase confidence in standard single-gate TCD spectral findings.


Subject(s)
Brain Ischemia/diagnostic imaging , Infarction, Posterior Cerebral Artery/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods , Ultrasonography, Doppler, Transcranial/standards , Acute Disease , Aged , Aged, 80 and over , Angiography, Digital Subtraction , Cerebral Angiography , False Positive Reactions , Female , Humans , Magnetic Resonance Angiography , Male , Middle Aged , Reproducibility of Results , Tomography, X-Ray Computed
14.
Exp Neurol ; 206(1): 95-100, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17509567

ABSTRACT

Peri-infarct increase of vascular density has been observed in animals and in humans with ischemic stroke. Increased peri-infarct vascular density correlates with improved functional outcome after stroke. We hypothesized that pre-treatment with estradiol will increase post-ischemic peri-infarct capillary density in a rat model of transient ischemic stroke. Estradiol, compared to placebo, augmented post-ischemic peri-infarct vascular density by 22% 10 days after stroke. Recovery of forelimb function was not improved with estradiol treatment on day three and nine post-stroke. Loss of estradiol may limit repair in the peri-infarct region by limiting angiogenesis, but functional significance in stroke recovery requires further investigation.


Subject(s)
Angiogenesis Inducing Agents/pharmacology , Brain Infarction/drug therapy , Cerebral Arteries/drug effects , Estradiol/pharmacology , Neovascularization, Physiologic/drug effects , Stroke/drug therapy , Angiogenesis Inducing Agents/therapeutic use , Animals , Brain Infarction/physiopathology , Capillaries/drug effects , Capillaries/physiology , Cerebral Arteries/physiopathology , Disease Models, Animal , Estradiol/therapeutic use , Female , Forelimb/innervation , Forelimb/physiopathology , Microcirculation/drug effects , Microcirculation/physiology , Motor Cortex/blood supply , Motor Cortex/drug effects , Motor Cortex/physiopathology , Neovascularization, Physiologic/physiology , Paresis/drug therapy , Paresis/etiology , Paresis/physiopathology , Rats , Rats, Wistar , Recovery of Function/drug effects , Recovery of Function/physiology , Stroke/physiopathology , Telencephalon/blood supply , Telencephalon/drug effects , Telencephalon/physiopathology , Treatment Outcome
15.
Arch Neurol ; 63(11): 1643-6, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17101836

ABSTRACT

BACKGROUND: Cervical epidural steroid injection treatment of radicular pain has become a common procedure. OBJECTIVES: To describe the clinical, radiologic, and autopsy findings of a 41-year-old patient treated with methylprednisolone acetate cervical epidural steroid injection, who developed a fatal hemorrhagic brainstem infarction and to discuss the possible mechanisms involved. DESIGN: Case report. SETTING: Pain management center and tertiary care hospital. RESULTS: Immediately following a seemingly uncomplicated epidural steroid injection at C5-6, the patient developed progressive symptoms of extensive brainstem and thalamic infarction (documented by magnetic resonance imaging and autopsy) with hemorrhagic conversion and hydrocephalus. Hemorrhage within the adventitia of the left vertebral artery, but no dissection, was found at the C5 vertebral level at necropsy. CONCLUSIONS: This case report shows the possibility of serious intracranial pathology resulting from cervical epidural steroid injection despite use of fluoroscopic guidance. Vascular spasm distant to the site of injection is a possible mechanism.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Brain Stem Infarctions/chemically induced , Methylprednisolone/analogs & derivatives , Adult , Brain Stem Infarctions/pathology , Cervical Vertebrae/drug effects , Humans , Injections, Epidural/methods , Magnetic Resonance Angiography/methods , Magnetic Resonance Imaging/methods , Male , Methylprednisolone/adverse effects , Methylprednisolone Acetate , Pain/drug therapy
16.
Neurology ; 67(5): 917-8, 2006 Sep 12.
Article in English | MEDLINE | ID: mdl-16966573
17.
Stroke ; 36(2): 337-41, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15637314

ABSTRACT

BACKGROUND AND PURPOSE: Female, compared with male, animals are protected from cerebral ischemic injury. Physiological concentrations of 17beta-estradiol (E2) reduce damage in experimental stroke. E2 augments angiogenesis in reproductive organs and noncerebral vascular beds. We hypothesized that E2 protects brain in stroke through modulation of angiogenesis. We quantified molecular markers of angiogenesis and capillary density before and after unilateral middle cerebral artery occlusion (MCAO). METHODS: Female animals were ovariectomized, treated with 25 microg E2 or placebo implants, and subjected to 2-hour MCAO and 22 hours of reperfusion. Brain angiopoietin-1 (Ang-1), Ang-2, Tie-1, Tie-2, vascular endothelial growth factor (VEGF), VEGF R1, and VEGF R2 mRNA levels were determined by RNAse protection assays, and CD31-positive vessels were counted. RESULTS: E2, but not ischemia, upregulated cerebral Ang-1 mRNA by 49%. Capillary density was higher in the brains of E2-treated animals. In estrogen receptor-alpha knockout (ERKO) mice, E2-mediated induction of Ang-1 mRNA was absent relative to wild-type littermates. CONCLUSIONS: These results suggest that E2 increases Ang-1 and enhances capillary density in brain under basal conditions, priming the MCA territory for survival after experimental focal ischemia.


Subject(s)
Angiopoietin-1/metabolism , Capillaries/metabolism , Estradiol/pharmacology , Estrogen Receptor alpha/metabolism , Gene Expression Regulation , Stroke/genetics , Animals , Brain/metabolism , Brain/pathology , Disease Models, Animal , Estradiol/metabolism , Female , Infarction, Middle Cerebral Artery/metabolism , Mice , Mice, Knockout , Neovascularization, Pathologic , Placebos , Platelet Endothelial Cell Adhesion Molecule-1/biosynthesis , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Estrogen/genetics , Reperfusion Injury , Ribonucleases/metabolism , Temperature , Time Factors , Transcription, Genetic , Up-Regulation , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL